An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR

被引:208
作者
Hou, Guiqin [1 ]
Xue, Lexun [1 ]
Lu, Zhaoming [1 ]
Fan, Tianli [1 ]
Tian, Fang [1 ]
Xue, Yanli [1 ]
机构
[1] Zhengzhou Univ, Cell Biol Lab, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
关键词
mTOR; p70S6K; Rapamycin; siRNA; Apoptosis; esophageal squamous cell carcinoma;
D O I
10.1016/j.canlet.2007.01.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
mTOR/p70S6K pathway is considered a central regulator in various malignant tumors, but its roles in esophageal squamous cell carcinoma (ESCC), which is a common cause of mortality in China, remain unknown. Here, we identify that the mTOR/p70S6K pathway is activated in ESCC; rapamycin and siRNA against mTOR rapidly inhibited expression of mTOR and the phosphorylation of its major downstream effectors, p70S6K and 4E-BP1, arrested cells in the G(0)/G(1) phase and induced apoptosis of ESCC cells. The findings may lay a foundation for making further investigations on the mTOR/p70S6K pathway as a potential target for ESCC therapy. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:236 / 248
页数:13
相关论文
共 43 条
[1]
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck [J].
Amornphimoltham, P ;
Patel, V ;
Sodhi, A ;
Nikitakis, NG ;
Sauk, JJ ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CANCER RESEARCH, 2005, 65 (21) :9953-9961
[2]
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation [J].
Asano, T ;
Yao, YX ;
Zhu, JJ ;
Li, DH ;
Abbruzzese, JL ;
Reddy, SA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 331 (01) :295-302
[3]
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[4]
Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells [J].
Beevers, Christopher S. ;
Li, Fengjun ;
Liu, Lei ;
Huang, Shile .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) :757-764
[5]
The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[6]
New targets for therapy in breast cancer - Mammalian target of rapamycin (mTOR) antagonists [J].
Carraway, H ;
Hidalgo, M .
BREAST CANCER RESEARCH, 2004, 6 (05) :219-224
[7]
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].
Chan, S .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424
[8]
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway [J].
deGraffenried, LA ;
Fulcher, L ;
Friedrichs, WE ;
Grünwald, V ;
Ray, RB ;
Hidalgo, M .
ANNALS OF ONCOLOGY, 2004, 15 (10) :1510-1516
[9]
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity [J].
DeGraffenried, LA ;
Friedrichs, WE ;
Russell, DH ;
Donzis, EJ ;
Middleton, AK ;
Silva, JM ;
Roth, RA ;
Hidalgo, M .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8059-8067
[10]
Dudkin L, 2001, CLIN CANCER RES, V7, P1758